Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
Caserta S et al.
European Journal of Haematology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.
Molica S et al.
Cancers, 2025
Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform.
Dimou M et al.
Leukemia & Lymphoma, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
In Silico Investigation of BTK as a Potent Immunomodulatory Target: Exploring Novel Therapeutic Approaches for Multiple Sclerosis.
Saba A et al.
Acs Omega, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Garcia M et al.
Annals of Hematology, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Brown JR et al.
Blood Advances, 2025
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures.
Darragh AC et al.
Acs Pharmacology & Translational Science, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Gandhi V et al.
Research Square, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.
Lin C et al.
Hematology Reports, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.
Aslan B et al.
Blood Advances, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA et al.
Blood, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F et al.
Leukemia, 2024
The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas.
Mehra S et al.
International Journal of Molecular Sciences, 2024
New Means and Challenges in the Targeting of BTK.
Nawaratne V et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C et al.
Blood Advances, 2024
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K et al.
International Journal of Molecular Sciences, 2024
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW et al.
Haematologica, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S et al.
Science (new York, N.y.), 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A et al.
Genes, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB et al.
Blood, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.
Frustaci AM et al.
Cancers, 2023
Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS et al.
Blood Advances, 2023
BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma.
Yuan H et al.
The Journal of Biological Chemistry, 2022
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B et al.
Blood Cancer Journal, 2022
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Thompson ER et al.
Blood Advances, 2022